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Abstract
Background: Factor V (FV) in its activated form, FVa, is a critical regulator of thrombin generation during fibrin clot
formation. There is a need of a simple, fast, and inexpensive microplate-based coagulation assay to measure the
functional activity of FV in human plasma. The objective of this study was to develop a microplate-based assay
that measures FV coagulation activity during clot formation in human plasma, which is currently not available.
Methods: The FV assay requires a kinetic microplate reader to measure the change in absorbance at 405nm
during fibrin formation in human plasma. The FV assay accurately measures the time, initial rate, and extent of
fibrin clot formation in human plasma.
Results: The FV microplate assay is simple, fast, economical, sensitive to approx 24-80pM, and multiple samples
may be analyzed simultaneously. All the required materials are commercially available. Standard curves of time or
initial rate of fibrin clot formation vs FV activity in the 1-stage assay (Without activation by thrombin) may be used
to measure FV activity in samples of human plasma. The assay was used to demonstrate that in nine patients with
disseminated intravascular coagulation (DIC), the FV 1-stage, 2-stage (With activation by thrombin), and total (2-
stage activity - 1-stage activity) activities were decreased, on average, by approximately 54%, 44%, and 42%,
respectively, from prolonged clot times when compared to normal pooled human reference plasma (NHP). The
results indicate that the FV in the DIC patient plasmas supported both a delayed and slower rate of fibrin clot
formation compared with NHP; however, the extent of fibrin clot formation in the DIC patients remained largely
unchanged from that observed with NHP.
Conclusions: The FV microplate assay may be easily adapted to measure the activity of any coagulation factor
using the appropriate factor-deficient plasma and clot initiating reagent. The microplate assay will find use in both
research and clinical laboratories to provide measurement of the functional coagulation activity of FV in human
plasma.
Background
The use of microplate-based assays for quantification of
enzyme activity is now common practice in many labora-
tories for enzyme linked immunosorbant assays [1] and
colorimetric enzyme assays using chromogenic substrates
[2]. The two main advantages for microplate-based assays
are use of small sample volumes and that multiple sam-
ples may be analyzed simultaneously. Several microplate
assays have been previously reported for measurement of
clot lysis [3], platelet aggregation [4], the activity of Fac-
tor (F) VII, VIII, IX and IXa, X, XI, XII, and activated
protein C (APC) [5,6]. General coagulation and fibrinoly-
sis microplate assays have also been described [7]. Finally,
although manual [8,9] and automated [10] FV coagula-
tion assays have been described, no microplate-based
coagulation assay has been previously reported to mea-
sure FV activity in human plasma.
FV circulates in humans at approx 12-40nM as an inac-
tive procofactor of Mr 330kDa [11]. In response to injury,
activation of FV to the activated cofactor, FVa, occurs
initially by thrombin [12]. FVa is a major regulatory com-
ponent of coagulation where it accelerates thrombin gen-
eration and consequent fibrin clot formation as part of
the prothrombinase enzyme complex [13]. In the pre-
sence of thrombomodulin, thrombin activates protein C
to activated C (APC) which inactivates FV and FVa and
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downregulates coagulation as part of the normal anticoa-
gulation response to injury [14]. The FV Leiden mutation
(Arg 506 to Gln) results in FVa becoming resistant to
APC inactivation and results in a hypercoagulable state
in affected individuals [15]. The FV Leiden mutation is
currently the most common genetic risk factor for
venous thrombosis in humans [16].
Although methods for determining the FV 1-stage activ-
ity (Without activation by thrombin) in human plasma
using manual tilt-tube assays have been described [8,9],
the results may be prone to operator bias. Further, these
FV assays are time consuming because only one sample
may be assayed at a time. Since FV circulates in plasma as
an inactive procofactor [11], it must be ‘intentionally’ acti-
vated with added thrombin to generate FVa for accurate
and complete measurement of the FV 2-stage activity
(With activation by thrombin). The total FV activity may
then be calculated using the measurements from FV 1-
and 2-stage assays (Total FV activity = 2-stage activity - 1-
stage activity). Methods for determining the FV 2-stage
activity in plasma using tilt-tube [8,9] and automated [10]
formats have been described.
The equipment required to perform automated coagu-
lation assays is expensive. Although these analyzers are
generally used in clinical laboratories to measure clot
times in patient plasmas, the rate and extent of clot for-
mation are not routinely assessed. The FV microplate
assay described here provides measurement of the time,
initial rate, and extent of clot formation in human plasma
in a fast and convenient manner. It may be easily adapted
to measure the activity of any coagulation factor in the
extrinsic, intrinsic, or common pathway using the appro-
priate factor-deficient plasma and clot initiating reagent.
This new microplate-based coagulation assay will be use-
ful in both research and clinical laboratories to increase




Normal pooled human reference plasma (NHP) was
obtained from Precision Biologicals (Dartmouth, NS,
Canada) and was stored at -80°C until use. Fresh frozen
human plasma was obtained from Lakeridge Healthcare
(Oshawa, ON, Canada) and stored at -80°C until use.
FV-deficient plasma was made from fresh frozen human
plasma according to Bloom et al. [9], dialyzed exhaus-
tively against 20mM HEPES, 0.15M NaCl, pH 7.4
(HBS), and stored at -80°C until use. The FV-deficient
plasma contained less than 0.1% of the active FV present
in the original fresh frozen human plasma. Thrombo-
plastin reagent from Trinity Biotech (Wicklow, Ireland)
was reconstituted with and dialyzed exhaustively against
HBS at 4°C, and stored at -80°C until use. Dialysis was
required to remove any calcium in this reagent in order
to permit precisely timing the reaction from the time of
addition of calcium chloride to initiate clotting (See
below). Purified thrombin was prepared according to
Bajzar et al. [17]. The nine patients studied were diag-
nosed with disseminated intravascular coagulation (DIC)
at some point during their stay in the Intensive Care
Unit of The Royal Liverpool University Hospital (Liver-
pool, UK) according to The International Society on
Thrombosis and Haemostasis Scientific and Standardiza-
tion Committee algorithm [18]. Patients were treated
according to standard procedures and none received
heparin or anticoagulant factor concentrates. Patient
blood samples were drawn into 0.1 volume of 3.8%
sodium citrate according to The Liverpool Research
Ethics Committee and the plasma fractions were stored
at -80°C until use. To determine the normal range of
FV activity in the FV 1-stage microplate assay, approxi-
mately 4.5 ml of blood was drawn from 15 healthy sub-
jects (Age 18-22 years) from the Medical Laboratory
Science Program at The University of Ontario Institute
of Technology into 0.5 ml of 3.8% sodium citrate and
the plasma fractions were stored at -80°C until use. The
research complied with all relevant laws, guidelines, and
policies. Thawed/refrozen aliquots of NHP, FV-deficient
plasma, thromboplastin, and patient plasma were not
used for study.
Factor V Coagulation Assays
The FV microplate assay was performed in the wells of
immunomodule strips (Nunc, Roskilde, Denmark) using
a multichannel pipette to make simultaneous additions of
FV-deficient plasma (50 μl), followed by normal or
patient plasma diluted in HBS (50 μl), and finally throm-
boplastin (50 μl). The samples were incubated in a Spec-
tra Max 190 microplate reader (Molecular Devices,
Sunnyvale, CA, USA) at 25°C for 1 minute with shaking
during the 15-25 seconds of the 1 minute incubation.
Calcium chloride (50 μl of 25mM) was then added to
initiate clotting. The samples were then shaken for 10 sec-
onds and the absorbance at 405nm was read every 5 sec-
onds for 6 minutes. The 10 seconds required for shaking
prior to absorbance readings were not included in the
calculated clot times. The clot times were calculated as
the time to reach the midpoint between the minimum
and maximum absorbance at 405nm after calcium chlor-
ide addition. The initial rate of clot formation was calcu-
lated as the rate of increase in absorbance at 405nm
(mUnits/minute) using the first 5 time points of clot for-
mation in the linear portion of the absorbance vs time
curve. The extent of clot formation was calculated as the
difference between the maximal and minimal absorbance
in Units at 405nm achieved during the clot formation
event.
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The FV 1-stage activity of a plasma sample diluted 40-
fold in HBS was determined by comparison to the FV 1-
stage microplate assay standard curves of times or initial
rates of clot formation vs FV activity measured upon serial
dilution of NHP (0- to 1024-fold) in HBS. One unit of FV
activity was defined as the activity in 1 ml of NHP prior to
activation by thrombin (See below). Up to 12 samples
were analyzed simultaneously using SOFTmax PRO 4.3
LS software (Molecular Devices, Sunnyvale, CA, USA).
The above microplate assay measures the FV 1-stage activ-
ity (Without activation by thrombin) of a plasma sample.
Since FV is activated with thrombin to the active cofactor,
FVa [12], a second assay after addition and incubation
with thrombin was critical to accurately measure the FV
2-stage (With activation by thrombin) cofactor activity of
a plasma sample. For the FV 2-stage assay, purified throm-
bin (1 Unit/ml; 10nM final concentration) was added to
the plasma sample diluted 100-fold in HBS and incubated
for 1 minute at 37°C. The plasma sample was diluted a
further 5-fold in HBS and re-assayed at a 500-fold dilution
as described above. The FV 2-stage activity was interpo-
lated from the FV 1-stage assay standard curve of time of
clot formation vs FV activity (See above). The total FV
activity was calculated from the measured values from the
FV 2-stage and 1-stage assays and was defined as the 2-
stage activity - 1-stage activity.
The results shown for the times and initial rates of
clot formation in the FV 1-stage assay standard curves
are representative of experiments conducted on greater
than thirty different occasions. The intra- and inter-FV
assay variability of the time, extent, and initial rate of
clot formation were calculated from six samples of NHP
diluted 40-fold in HBS on eight different days.
Results
A typical depiction of clot formation in the FV coagula-
tion assay over time generated by the microplate reader
is shown in Figure 1. Visual inspection of the wells after
the assay was performed confirmed that clot formation
took place. All reactions reached approximately the same
extent of clot formation with a typical change in absor-
bance at 405nm of 0.35 - 0.45 Units between the starting
absorbance before and the maximal absorbance after
thromboplastin and calcium chloride addition.
In order to measure the FV activity in a plasma sample,
standard curves of time and initial rate of clot formation vs
FV 1-stage activity were generated upon serial dilution of
NHP. Fitting the Log-Log plot of clot time vs FV 1-stage
activity demonstrated a strong linear relationship between
these variables after regression analysis (Figure 2A; R2 =
0.980). Fitting of the Log-Log plot of the initial rate of clot
formation vs FV 1-stage activity also demonstrated a strong
linear relationship between these variables after regression
analysis (Figure 2B; R2 = 0.983). The relationship of both
clot time and initial rate of clot formation vs FV 1-stage
activity remained linear in NHP diluted up to approx
1024-fold. Given that the FV concentration in NHP is
approx 12-40nM [11], the results indicate that the assay is
sensitive to approximately 24-80pM FV in NHP. Our
results indicate that the normal range of FV activity in the
FV 1-stage activity assay in 15 healthy controls assayed
with the FV microplate assay was approximately (Mean ±
Standard deviation; Range): 0.96 ± 0.14 U/ml; 0.68-1.11
U/ml. This is similar to the FV activity and range (0.66-
1.14 U/ml) in healthy controls reported by Cutler et al.
for the FV 1-stage activity measured with an automated
analyzer [19].
Under the conditions of the assay using 40-fold diluted
NHP, the intra-assay variability of the time, extent, and
initial rate of clot formation in the FV 1-stage assay
among 6 wells on 8 different days was 3.4%, 4.4%, and
3.1%, respectively. The inter-assay variability of the time,
extent, and initial rate of clot formation in the FV 1-stage
assay among 6 wells of 8 different experiments on 8 differ-
ent days was 7.1%, 7.8%, and 9.2%, respectively. Thus, the
intra- and inter-assay variability of these three variables in
the FV 1-stage assay was at a low and acceptable level.
Figure 1 Monitoring clot formation in normal pooled human
reference plasma with the kinetic microplate FV 1-stage
coagulation assay. Fibrin clot formation in NHP was monitored at
405nm over time in a microplate reader. The profile represents the
actual microplate reader output of a 6 minute reaction of 32-fold
diluted NHP, FV-deficient plasma, thromboplastin, and calcium
chloride in a single microplate well. The vertical axis denotes the
change in absorbance at 405nm that occurred as a result of clot
formation in plasma. The time of fibrin formation was defined as
the time to reach the half maximal increase in absorbance;
approximately the midpoint of curve (36.40 seconds). The initial rate
of clot formation was defined as the rate of change of absorbance
at 405nm over the first 5 time points of the linear increase of
absorbance portion of the curve (611.88 mUnits/min). The extent of
clot formation was defined as the difference between the
maximum and minimum absorbance at 405nm (0.35 Units).
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The standard curve of clot time vs FV 1-stage activity
(Figure 2A) was used to measure the FV activity in nine
DIC patient plasmas which were (FV 2-stage activity) or
were not (FV 1-stage activity) intentionally activated with
thrombin and the results are shown in Table 1. All nine
DIC patient plasmas exhibited FV 1-stage activities and
initial rates of clot formation that were decreased on aver-
age, by approx 54% and 18%, respectively, from NHP. The
extents of clot formation in the FV 1-stage assay in the
DIC patients were not largely different from NHP, and
increased on average, by approx 13% from NHP.
Activation of NHP with thrombin generated an approxi-
mate 8-fold increase in FV 2-stage activity above the FV 1-
stage activity (Table 1). This indicates that the FV in NHP
was mainly present in its unactivated form and is
consistent with the results reported by Nesheim et al.
using a manual tilt-tube FV assay [8]. The FV 2-stage and
total activity were also decreased in the DIC patients on
average, by approx 44% and 42%, respectively, from NHP.
The initial rates and extents of clot formation in the FV 2-
stage assay in the DIC patients were not largely different
from NHP, and varied on average, by approx 9% and 4%,
respectively, from that observed with NHP.
Discussion
The kinetic microplate-based assay outlined here
describes the development of a new, fast, economical,
and simple technique for measurement of FV coagula-
tion activity in samples of human plasma which has or
has not been intentionally activated by thrombin. The
assay requires a kinetic microplate reader and all the
required reagents and materials are commercially avail-
able. The assay measures the increase in turbidity of
plasma during clot formation at 405nm using a kinetic
plate reader. The assay also has the added advantage of
using small sample volumes (50 μl) as well as being able
to analyze multiple samples simultaneously (up to 12).
These assay characteristics are especially important and
advantageous when expensive reagents are required
such as factor-deficient plasmas; when only small sam-
ple volumes are available such as patient plasmas or
when analyzing a large number of samples during purifi-
cation of FV from plasma.
The results indicate that the FV in the DIC patient
plasmas was functionally less active than in NHP
because of prolonged clot times and decreased initial
rates of clot formation in the FV 1-stage assay. However,
the initial rates of clot formation in the FV 2-stage assay
in the DIC patients were not largely different from
NHP. The extents of clot formation in the DIC patient
plasmas were also not largely different from NHP in the
FV 1-stage and 2-stage assays. Since the extent of clot
formation in the DIC patient plasmas was the same as
observed with NHP, this was most likely determined by
the fibrinogen level in the FV-depleted plasma and
unrelated to characteristics of the patient plasmas.
These results indicate that the FV in the DIC patient
plasmas supported both a delayed and slower rate of
fibrin clot formation compared with NHP; however, the
extent of fibrin clot formation in the DIC patients
remained largely unchanged from that observed with
NHP. Compared with NHP, the FV in the DIC patient
plasmas was also on average, 44% less activatable with
thrombin in the FV 2-stage assay. Finally, the FV total
activity in the DIC patients decreased by approx 42% on
average, from that observed in NHP. The decreased FV
1-stage, 2-stage, and total activities may have been due
to increased FV consumption [20] and/or inactivation
[21] which occurred during the pathogenesis of this
Figure 2 Standard curves of time and initial rate of clot
formation vs Factor V activity in normal pooled human
reference plasma using the FV 1-stage microplate assay. NHP
was serially diluted (0- to 1024-fold in HBS) and assayed with the FV
1-stage microplate assay as described in the text. Log-Log plots of
the times and initial rates of clot formation vs FV activity in the FV
1-stage microplate assay are shown after linear regression modelling
of the results in panels A and B, respectively.
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acquired blood disorder in the patients studied. Our
preliminary results indicate that the FV antigen levels in
the DIC patient plasmas studied were not significantly
different from NHP [11], which indicates a qualitative
disorder of FV occurred in this condition.
The results of the microplate assay indicate that mea-
surement of FV coagulation activity in human plasma
samples may be obtained from the time and initial rate
measurements of clot formation from the FV 1-stage
assay and the time of clot formation and total activity
measurement from the FV 2-stage assay. It was however
not possible to obtain a quantitative measurement of FV
coagulation activity in a plasma sample based on the
extent of clot formation in the FV 1- and 2-stage assays
or the initial rate of clot formation in the FV 2-stage
assay. Since all reactions reached approximately the same
extent of clot formation at 405nm of 0.35 - 0.45 Units
between the starting absorbance before and the maximal
absorbance after thromboplastin and calcium chloride
addition, measurement of the extent of clot formation
does not strictly provide a quantitative measurement of
FV coagulant activity in any given plasma sample.
The new microplate assay will be useful in both clinical
and research laboratories for measurement of FV activity
in human plasma samples. The microplate assay may be
used to measure the time, initial rate, and extent of clot
formation; parameters not routinely monitored simulta-
neously in most automated coagulation analyzers. In its
entirety, this quantitative information provides more of a
complete ‘picture’ of the involvement of FV during the
clot formation event in human plasma than has been pre-
viously reported [5,7-10,21]. This information, in turn,
may be especially important in both research and clinical
settings when assessing significant changes in FV activity
in plasma samples or using purified FV or FVa. Other
applications of the FV assay include its use to detect and
measure compounds and substances that may activate or
inactivate FV or FVa, measure the FV activity in patients
at risk for venous thrombosis as a result of the FV Leiden
mutation [15,16], and to measure the FV activity during
its purification from either human or animal plasma.
Conclusion
The FV microplate assay format may be easily adapted
to measure the activity of any coagulation factor in the
extrinsic, intrinsic, or common pathway using the
appropriate factor-deficient plasma and clot initiating
reagent. The clinical and research use of this new
microplate-based coagulation assay will provide further
information and understanding of FV biochemistry and
functional activity in the future.
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NHP 1.02 0.363 744.96 7.93 0.433 375.84 6.91
Patient 1 0.36 0.404 583.80 3.84 0.432 249.96 3.48
Patient 2 0.67 0.416 704.04 5.28 0.469 323.16 4.61
Patient 3 0.31 0.435 562.08 3.92 0.453 294.96 3.61
Patient 4 0.39 0.435 617.04 4.14 0.462 372.60 3.75
Patient 5 0.73 0.401 641.40 5.91 0.433 354.24 5.18
Patient 6 0.45 0.403 600.72 4.16 0.445 393.96 3.71
Patient 7 0.49 0.395 575.40 4.89 0.449 357.48 4.40
Patient 8 0.19 0.448 489.00 2.89 0.450 330.48 2.70
Patient 9 0.64 0.423 699.48 5.11 0.455 417.24 4.47
The FV 1-stage, 2-stage, and total activity in normal pooled human reference plasma (NHP) and the 9 DIC patient plasma samples were determined from the FV
1-stage microplate assay standard curve of time of clot formation vs FV activity (Figure 2A) and are given in Units/ml. The initial rates (Initial rate of increase in
A405nm over first five time points in mUnits/min) and extents (Maximum A405nm - Minimum A405nm) of clot formation in the FV 1- and 2-stage microplate
assay are also shown.
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